Sanofi profit gain exceeds market view on best-selling drug Dupixent

0

Sanofi logo at the company’s headquarters during the annual earnings news conference in Paris, France, February 4, 2022. REUTERS/Benoit Tessier

Join now for FREE unlimited access to Reuters.com

Register

April 28 (Reuters) – French health group Sanofi’s (SASY.PA) adjusted first-quarter profit rose 16.2% on growing sales of its top-selling drug Dupixent and a rebound in demand non-prescription drugs.

First-quarter business operating profit, or adjusted earnings before interest and tax, reached 3.07 billion euros ($3.23 billion), beating analysts’ average estimate of 2.84 billion. euros published on the company’s website.

The drugmaker added that it would stop recruiting patients for clinical trials in Russia and Belarus, following Russia’s attack on Ukraine, which would delay the results of studies in the field of multiple sclerosis and chronic obstructive pulmonary disease (COPD).

Join now for FREE unlimited access to Reuters.com

Register

The timeline for regulatory approval applications, however, remained unchanged, he added.

Last month, the company said peak annual sales of Dupixent, co-developed with Regeneron (REGN.O), would be more than 13 billion euros, against a previous target of more than 10 billion. Read more

The potential use of the COPD drug, sometimes called smoker’s lung, would add to that and trial results were so far expected next year.

Sanofi said on Thursday it still expects the group’s adjusted earnings per share for 2022 to grow by a low double-digit percentage.

Revenue from eczema and asthma treatment Dupixent jumped more than 45% to 1.61 billion euros, beating an analyst consensus of 1.58 billion euros, on dermatitis prescriptions , asthma and certain nasal infections.

The French group added that it and its partner GlaxoSmithKline (GSK.L), which have fallen behind in the race to launch a COVID-19 vaccine, are working on a next-generation booster vaccine for broad protection against all coronavirus variants of concern, with trial data expected in the second quarter of this year.

($1 = 0.9500 euros)

Join now for FREE unlimited access to Reuters.com

Register

Reporting by Ludwig Burger; Editing by Sudip Kar-Gupta and Uttaresh.V

Our standards: The Thomson Reuters Trust Principles.

Share.

Comments are closed.